Ginsenoside CK ameliorates hepatic lipid accumulation via activating LKB1/AMPK pathway in vitro and in vivo
期刊名：Royal Society of Chemistry
文献编号：
文献地址： https://pubs.rsc.org/en/content/articlehtml/2022/fo/d1fo03026d
发表日期：15th December 2021
文献编号：
文献地址： https://pubs.rsc.org/en/content/articlehtml/2022/fo/d1fo03026d
发表日期：15th December 2021
Nonalcoholic fatty liver disease (NAFLD) is a metabolic liver disease with complex etiology, which is considered as one of the main causes of hepatocellular carcinoma (HCC). The incidence of NAFLD has presented an increasing trend annually as a result of disequilibrium in the dietary structure. However, no specific treatment has been approved for clinical therapy in NAFLD. Ginsenoside CK has been investigated given its various pharmacological activities, but its effects against NAFLD and the underlying mechanism are still unclear. In this study, fructose and free fatty acids (FFA) were used to simulate hepatic fatty degeneration in vivo and in vitro, respectively. The level of lipid accumulation in hepatic tissue and HepG2 cells were evaluated by Oil Red O staining. Detection of serum and liver biomarkers, western blotting, and real-time qPCR were conducted to assess the degree of hepatic steatosis. Our results indicated that ginsenoside CK could decrease the lipid deposition in HepG2 cells, retard the increase of body weight of fructose-fed mice, alleviate the lipid accumulation in serum and hepatic tissue as well as improve the hepatic inflammation and injury. Mechanically, ginsenoside CK modulated the expression of factors correlated with lipid synthesis and metabolism in vitro and in vivo via activating the phosphorylation of LKB1 and AMPK. Compound C, an inhibitor of AMPK, partially abrogated the beneficial effects of ginsenoside CK in HepG2 cells. In summary, ginsenoside CK acts as a LKB1/AMPK agonist to regulate lipid metabolism and interfere with the progression of NAFLD.
相关产品
